Skip to main content
FDA Acceptance of Supplemental New Drug Application for UZEDY® as a Treatment for Patients with Bipolar I Disorder
February 25, 2025
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia
February 10, 2025
The EIB Reaffirms Confidence in Medincell by Permanently Waiving Two Financial Covenants in its Loan Agreement
February 6, 2025
UZEDY® Surges to $117M in Sales in 2024, First Full Year of Commercialization
January 29, 2025
2025 Financial Calendar
January 15, 2025
Medincell to Join the Euronext SBF 120 Index
December 12, 2024
[Replay] Videoconference – H1 2024-25 Results
December 10, 2024
Consolidated Half-Year Financial Results
December 10, 2024
